LB Pharmaceuticals (LBRX) Competitors $28.12 +0.12 (+0.43%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$28.34 +0.22 (+0.76%) As of 05/22/2026 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LBRX vs. ERAS, TWST, RCUS, TNGX, and DNLIShould you buy LB Pharmaceuticals stock or one of its competitors? MarketBeat compares LB Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with LB Pharmaceuticals include Erasca (ERAS), Twist Bioscience (TWST), Arcus Biosciences (RCUS), Tango Therapeutics (TNGX), and Denali Therapeutics (DNLI). These companies are all part of the "pharmaceutical products" industry. LBRX vs. ERASLBRX vs. TWSTLBRX vs. RCUSLBRX vs. TNGXLBRX vs. DNLIHow does LB Pharmaceuticals compare to Erasca?LB Pharmaceuticals (NASDAQ:LBRX) and Erasca (NASDAQ:ERAS) are both pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability. Do analysts rate LBRX or ERAS? LB Pharmaceuticals presently has a consensus price target of $38.40, indicating a potential upside of 36.56%. Erasca has a consensus price target of $18.75, indicating a potential upside of 66.81%. Given Erasca's higher possible upside, analysts clearly believe Erasca is more favorable than LB Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LB Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 2.88Erasca 2 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has stronger valuation and earnings, LBRX or ERAS? LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLB PharmaceuticalsN/AN/A-$25.20M-$1.73N/AErascaN/AN/A-$124.55M-$0.93N/A Is LBRX or ERAS more profitable? LB Pharmaceuticals' return on equity of 0.00% beat Erasca's return on equity.Company Net Margins Return on Equity Return on Assets LB PharmaceuticalsN/A N/A N/A Erasca N/A -35.31%-29.49% Does the media refer more to LBRX or ERAS? In the previous week, Erasca had 10 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 11 mentions for Erasca and 1 mentions for LB Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 0.00 beat Erasca's score of -0.16 indicating that LB Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LB Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Erasca 0 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Do institutionals & insiders have more ownership in LBRX or ERAS? 67.8% of Erasca shares are held by institutional investors. 14.2% of Erasca shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryErasca beats LB Pharmaceuticals on 7 of the 13 factors compared between the two stocks.How does LB Pharmaceuticals compare to Twist Bioscience?LB Pharmaceuticals (NASDAQ:LBRX) and Twist Bioscience (NASDAQ:TWST) are both pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings and risk. Is LBRX or TWST more profitable? LB Pharmaceuticals has a net margin of 0.00% compared to Twist Bioscience's net margin of -19.85%. LB Pharmaceuticals' return on equity of 0.00% beat Twist Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets LB PharmaceuticalsN/A N/A N/A Twist Bioscience -19.85%-26.73%-19.15% Do analysts recommend LBRX or TWST? LB Pharmaceuticals currently has a consensus price target of $38.40, indicating a potential upside of 36.56%. Twist Bioscience has a consensus price target of $58.00, indicating a potential downside of 4.24%. Given LB Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe LB Pharmaceuticals is more favorable than Twist Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LB Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 2.88Twist Bioscience 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75 Does the media favor LBRX or TWST? In the previous week, Twist Bioscience had 3 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 4 mentions for Twist Bioscience and 1 mentions for LB Pharmaceuticals. Twist Bioscience's average media sentiment score of 0.89 beat LB Pharmaceuticals' score of 0.00 indicating that Twist Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LB Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Twist Bioscience 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation & earnings, LBRX or TWST? LB Pharmaceuticals has higher earnings, but lower revenue than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than LB Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLB PharmaceuticalsN/AN/A-$25.20M-$1.73N/ATwist Bioscience$376.57M10.02-$77.67M-$1.33N/A SummaryLB Pharmaceuticals beats Twist Bioscience on 8 of the 13 factors compared between the two stocks.How does LB Pharmaceuticals compare to Arcus Biosciences?LB Pharmaceuticals (NASDAQ:LBRX) and Arcus Biosciences (NYSE:RCUS) are both pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends. Which has higher valuation & earnings, LBRX or RCUS? LB Pharmaceuticals has higher earnings, but lower revenue than Arcus Biosciences. LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLB PharmaceuticalsN/AN/A-$25.20M-$1.73N/AArcus Biosciences$247M11.95-$353M-$3.18N/A Is LBRX or RCUS more profitable? LB Pharmaceuticals has a net margin of 0.00% compared to Arcus Biosciences' net margin of -156.36%. LB Pharmaceuticals' return on equity of 0.00% beat Arcus Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets LB PharmaceuticalsN/A N/A N/A Arcus Biosciences -156.36%-68.97%-35.27% Does the media refer more to LBRX or RCUS? In the previous week, LB Pharmaceuticals and LB Pharmaceuticals both had 1 articles in the media. LB Pharmaceuticals' average media sentiment score of 0.00 equaled Arcus Biosciences'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LB Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arcus Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders hold more shares of LBRX or RCUS? 92.9% of Arcus Biosciences shares are owned by institutional investors. 9.6% of Arcus Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts prefer LBRX or RCUS? LB Pharmaceuticals currently has a consensus target price of $38.40, suggesting a potential upside of 36.56%. Arcus Biosciences has a consensus target price of $33.89, suggesting a potential upside of 44.36%. Given Arcus Biosciences' higher possible upside, analysts clearly believe Arcus Biosciences is more favorable than LB Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LB Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 2.88Arcus Biosciences 1 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.55 SummaryLB Pharmaceuticals beats Arcus Biosciences on 7 of the 13 factors compared between the two stocks.How does LB Pharmaceuticals compare to Tango Therapeutics?LB Pharmaceuticals (NASDAQ:LBRX) and Tango Therapeutics (NASDAQ:TNGX) are both pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk and analyst recommendations. Which has stronger valuation & earnings, LBRX or TNGX? LB Pharmaceuticals has higher earnings, but lower revenue than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than LB Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLB PharmaceuticalsN/AN/A-$25.20M-$1.73N/ATango Therapeutics$62.38M46.93-$101.59M-$0.83N/A Is LBRX or TNGX more profitable? LB Pharmaceuticals has a net margin of 0.00% compared to Tango Therapeutics' net margin of -151.15%. LB Pharmaceuticals' return on equity of 0.00% beat Tango Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets LB PharmaceuticalsN/A N/A N/A Tango Therapeutics -151.15%-41.54%-33.44% Does the media refer more to LBRX or TNGX? In the previous week, Tango Therapeutics had 3 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 4 mentions for Tango Therapeutics and 1 mentions for LB Pharmaceuticals. Tango Therapeutics' average media sentiment score of 0.17 beat LB Pharmaceuticals' score of 0.00 indicating that Tango Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LB Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tango Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate LBRX or TNGX? LB Pharmaceuticals currently has a consensus price target of $38.40, suggesting a potential upside of 36.56%. Tango Therapeutics has a consensus price target of $32.27, suggesting a potential upside of 59.45%. Given Tango Therapeutics' higher probable upside, analysts clearly believe Tango Therapeutics is more favorable than LB Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LB Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 2.88Tango Therapeutics 1 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.64 Do institutionals and insiders hold more shares of LBRX or TNGX? 79.0% of Tango Therapeutics shares are held by institutional investors. 6.5% of Tango Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. SummaryTango Therapeutics beats LB Pharmaceuticals on 8 of the 15 factors compared between the two stocks.How does LB Pharmaceuticals compare to Denali Therapeutics?Denali Therapeutics (NASDAQ:DNLI) and LB Pharmaceuticals (NASDAQ:LBRX) are both pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations. Does the media favor DNLI or LBRX? In the previous week, Denali Therapeutics and Denali Therapeutics both had 1 articles in the media. Denali Therapeutics' average media sentiment score of 0.88 beat LB Pharmaceuticals' score of 0.00 indicating that Denali Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LB Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher earnings & valuation, DNLI or LBRX? LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDenali TherapeuticsN/AN/A-$512.54M-$2.88N/ALB PharmaceuticalsN/AN/A-$25.20M-$1.73N/A Do insiders and institutionals believe in DNLI or LBRX? 92.9% of Denali Therapeutics shares are held by institutional investors. 12.5% of Denali Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts prefer DNLI or LBRX? Denali Therapeutics currently has a consensus target price of $34.25, indicating a potential upside of 83.74%. LB Pharmaceuticals has a consensus target price of $38.40, indicating a potential upside of 36.56%. Given Denali Therapeutics' higher possible upside, equities research analysts plainly believe Denali Therapeutics is more favorable than LB Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Denali Therapeutics 1 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.87LB Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 2.88 Is DNLI or LBRX more profitable? LB Pharmaceuticals' return on equity of 0.00% beat Denali Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Denali TherapeuticsN/A -52.20% -43.86% LB Pharmaceuticals N/A N/A N/A SummaryDenali Therapeutics and LB Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks. Get LB Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LBRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LBRX vs. The Competition ExportMetricLB Pharmaceuticals IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$802.95M$2.98B$4.24B$12.30BDividend YieldN/A15.25%6.21%5.31%P/E Ratio-16.2513.0621.9625.63Price / SalesN/A1,839.52177.3584.49Price / CashN/A26.3254.0456.72Price / Book2.136.1234.847.12Net Income-$25.20M-$42.06M$112.32M$335.28M7 Day Performance-5.19%0.87%1.85%2.98%1 Month Performance-8.61%1.86%3.84%2.85%1 Year PerformanceN/A18.72%15.98%35.17% LB Pharmaceuticals Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LBRXLB Pharmaceuticals1.6458 of 5 stars$28.12+0.4%$38.40+36.6%N/A$802.95MN/AN/A16ERASErasca3.5469 of 5 stars$10.27+0.4%$18.75+82.6%+828.9%$3.18BN/AN/A120TWSTTwist Bioscience1.6066 of 5 stars$49.79+1.3%$56.57+13.6%+115.1%$3.06B$376.57MN/A990Analyst ForecastRCUSArcus Biosciences2.7937 of 5 stars$23.43-1.5%$33.89+44.7%+167.4%$2.99B$247MN/A500TNGXTango Therapeutics2.7262 of 5 stars$20.63+0.3%$32.27+56.4%+985.3%$2.97B$62.38MN/A90 Related Companies and Tools Related Companies Erasca Alternatives Twist Bioscience Alternatives Arcus Biosciences Alternatives Tango Therapeutics Alternatives Denali Therapeutics Alternatives Alumis Alternatives Gemini Therapeutics Alternatives Beam Therapeutics Alternatives Dyne Therapeutics Alternatives MorphoSys Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LBRX) was last updated on 5/23/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...InvestorPlace | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LB Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share LB Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
